サンプル依頼リスト カート
  • English
  • Korean
デフォルト表紙
市場調査レポート
商品コード
1798908

HER2陽性胃がんの世界市場

HER2-Positive Gastric Cancer

出版日
ページ情報
英文 281 Pages
納期
即日から翌営業日
適宜更新あり
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=149.79円
HER2陽性胃がんの世界市場
出版日: 2025年08月27日
発行: Global Industry Analysts, Inc.
ページ情報: 英文 281 Pages
納期: 即日から翌営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

HER2陽性胃がんの世界市場は2030年までに3億2,240万米ドルに達する見込み

2024年に2億2,210万米ドルと推定されるHER2陽性胃がんの世界市場は、分析期間2024-2030年にCAGR 6.4%で成長し、2030年には3億2,240万米ドルに達すると予測されます。本レポートで分析したセグメントの1つである化学療法は、CAGR 7.2％を記録し、分析期間終了時には1億3,930万米ドルに達すると予測されます。標的療法分野の成長率は、分析期間中CAGR 6.8％と推定されます。

米国市場は6,050万米ドルと推定、中国はCAGR 10.2％で成長予測

米国のHER2陽性胃がん市場は、2024年に6,050万米ドルと推定されます。世界第2位の経済大国である中国は、分析期間2024-2030年のCAGRを10.2%として、2030年までに6,680万米ドルの市場規模に達すると予測されています。その他の注目すべき地域別市場としては、日本とカナダがあり、分析期間中のCAGRはそれぞれ3.1％と6.3％と予測されています。欧州では、ドイツがCAGR 4.2%で成長すると予測されています。

世界のHER2陽性胃がん市場- 主要動向と促進要因のまとめ

HER2陽性は胃がん診断の情勢をどう変えるか？

HER2陽性胃がんは、HER2（ヒト上皮成長因子受容体2）タンパク質の過剰発現を示す胃がんおよび胃食道接合部がんのサブセットを指します。HER2は乳がんに関連することが一般的であるが、胃がんにおけるHER2の役割は、標的治療の予測的価値により認知されつつあります。HER2の状態を正確に診断することは、現在、特に進行例や転移例において、患者を層別化し、治療レジメンを導くための重要なステップとなっています。

HER2陽性の検査は免疫組織化学（IHC）を用いて行われ、in situハイブリダイゼーション（ISH）法で確認されます。世界の腫瘍学ガイドラインでは、HER2標的治療の適格性を判断するために、新たに進行胃がんと診断された患者にHER2検査を推奨しています。このため、治療戦略を個別化し予後を改善するための精密診断が重視され、分子プロファイリングの臨床への統合が進んでいます。

HER2陽性胃がんに対してどのような標的治療が使用または開発されているか？

トラスツズマブは、HER2陽性胃がんの治療に用いられる最も確立された標的治療薬です。化学療法と併用することで、HER2過剰発現患者の生存成績が改善することが示されています。胃がんに対する承認後、HER2標的治療の範囲は拡大し、抗体薬物複合体、二重特異性抗体、チロシンキナーゼ阻害剤などの新しい薬剤が研究されています。

トラスツズマブ・デルクステカンなどの先進生物学的製剤は、一次治療に抵抗性を示す患者を対象に試験が行われており、臨床試験において有効性の改善が期待されています。免疫療法とHER2標的薬を統合した併用療法も評価中です。これらの技術革新は、胃がんにおけるHER2発現プロファイルや腫瘍特性に合わせた個別化治療のパイプラインが拡大していることを反映しています。

検査と治療の需要はどこで伸びているか、主要利害関係者は誰か？

HER2検査と標的治療の採用は、腫瘍センター、大学病院、診断研究所で拡大しています。需要は、東アジア、東欧の一部、ラテンアメリカなど、胃がん罹患率の高い地域で最も強いです。日本、韓国、中国は、がん医療システムが発達し、検査の普及率が高いため、主要な診断・治療市場となっています。

利害関係者には、がん専門医、病理検査室、製薬会社、診断アッセイ開発者が含まれます。診断薬メーカーと医薬品メーカーとの協力関係がコンパニオン診断薬や治療関連アッセイの開発を支えています。国のがん対策プログラムや公衆衛生イニシアチブは、バイオマーカー主導の治療モデルを通じてがんの生存率を向上させる幅広い取り組みの一環として、HER2スクリーニングをさらに奨励しています。

何がHER2陽性胃がん市場の成長を促進しているのか？

HER2陽性胃がん市場の成長は、胃がん罹患率の上昇、バイオマーカーに基づく治療計画の利用の増加、HER2標的治療へのアクセスの拡大など、いくつかの要因によってもたらされます。抗体ベースの検査や病理ワークフローの自動化など、診断精度の向上が正確なHER2同定を支えています。

腫瘍治療センター、診断ラボ、個別化薬剤開発プログラムにおける最終用途の拡大が市場開拓を強化しています。HER2指向性生物製剤のパイプラインの成長、既存薬の適応拡大、支持的な臨床ガイドラインは、治療の関連性を強化しています。個別化腫瘍学が進化を続ける中、HER2検査と治療は、生物学的に異なる胃がん患者層の管理において中心的な役割を果たすと予想されます。

セグメント

治療タイプ（化学療法、標的療法、免疫療法、併用療法）、エンドユーザー（病院エンドユーザー、専門がんセンターエンドユーザー、その他エンドユーザー）

調査対象企業の例

  • Acepodia Biotech Inc.
  • Astellas Pharma Inc.
  • AstraZeneca PLC
  • Bavarian Nordic A/S
  • Bellicum Pharmaceuticals
  • BioInvent International AB
  • Bristol-Myers Squibb
  • Carisma Therapeutics Inc.
  • Celularity Inc.
  • Daiichi Sankyo Co., Ltd.
  • Genentech（Roche Group）
  • GeneQuantum Healthcare
  • Hengrui（Jiangsu HengRui Medicine）
  • Imugene Limited
  • Klus Pharma Inc.
  • MacroGenics, Inc.
  • Merck & Co., Inc.
  • Mersana Therapeutics, Inc.
  • Novartis AG
  • Pfizer Inc.
  • Pieris Pharmaceuticals, Inc.
  • Shanghai Miracogen Inc.
  • Zymeworks Inc.

AIインテグレーション

当社は、有効な専門家コンテンツとAIツールにより、市場情報と競合情報を変革しています。

Global Industry Analystsは、一般的なLLMや業界固有のSLMにクエリーする代わりに、ビデオ記録、ブログ、検索エンジン調査、膨大な量の企業、製品/サービス、市場データなど、世界中の専門家からキュレートされたコンテンツのリポジトリを構築しました。

関税影響係数

Global Industry Analystsは、本社の国、製造拠点、輸出入（完成品とOEM）に基づく企業の競争力の変化を予測しています。この複雑で多面的な市場力学は、売上原価（COGS）の増加、収益性の低下、サプライチェーンの再構築など、ミクロおよびマクロの市場力学の中でも特に競合他社に影響を与える見込みです。

目次

第1章 調査手法

第2章 エグゼクティブサマリー

  • 市場概要
  • 主要企業
  • 市場動向と促進要因
  • 世界市場の見通し

第3章 市場分析

  • 米国
  • カナダ
  • 日本
  • 中国
  • 欧州
  • フランス
  • ドイツ
  • イタリア
  • 英国
  • スペイン
  • ロシア
  • その他欧州
  • アジア太平洋
  • オーストラリア
  • インド
  • 韓国
  • その他アジア太平洋地域
  • ラテンアメリカ
  • アルゼンチン
  • ブラジル
  • メキシコ
  • その他ラテンアメリカ
  • 中東
  • イラン
  • イスラエル
  • サウジアラビア
  • アラブ首長国連邦
  • その他中東
  • アフリカ

第4章 競合

目次
Product Code: MCP38903

Global HER2-Positive Gastric Cancer Market to Reach US$322.4 Million by 2030

The global market for HER2-Positive Gastric Cancer estimated at US$222.1 Million in the year 2024, is expected to reach US$322.4 Million by 2030, growing at a CAGR of 6.4% over the analysis period 2024-2030. Chemotherapy, one of the segments analyzed in the report, is expected to record a 7.2% CAGR and reach US$139.3 Million by the end of the analysis period. Growth in the Targeted Therapy segment is estimated at 6.8% CAGR over the analysis period.

The U.S. Market is Estimated at US$60.5 Million While China is Forecast to Grow at 10.2% CAGR

The HER2-Positive Gastric Cancer market in the U.S. is estimated at US$60.5 Million in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$66.8 Million by the year 2030 trailing a CAGR of 10.2% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 3.1% and 6.3% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 4.2% CAGR.

Global HER2-Positive Gastric Cancer Market - Key Trends & Drivers Summarized

How Is HER2 Positivity Changing the Landscape of Gastric Cancer Diagnosis?

HER2-positive gastric cancer refers to a subset of gastric and gastroesophageal junction cancers that exhibit overexpression of the HER2 (Human Epidermal Growth Factor Receptor 2) protein. While HER2 is more commonly associated with breast cancer, its role in gastric cancer is gaining recognition due to its predictive value for targeted therapy. Accurate diagnosis of HER2 status is now a key step in stratifying patients and guiding treatment regimens, particularly in advanced or metastatic cases.

Testing for HER2 positivity is conducted using immunohistochemistry (IHC) and confirmed with in situ hybridization (ISH) techniques. Global oncology guidelines recommend HER2 testing in newly diagnosed advanced gastric cancer patients to determine eligibility for HER2-targeted therapy. This has led to increasing integration of molecular profiling into clinical practice, with an emphasis on precision diagnostics to personalize treatment strategies and improve prognosis.

What Targeted Therapies Are Being Used or Developed for HER2-Positive Gastric Cancer?

Trastuzumab is the most established targeted therapy used for treating HER2-positive gastric cancer. Administered in combination with chemotherapy, it has shown improved survival outcomes in patients with HER2 overexpression. Following its approval for gastric cancer, the scope of HER2-targeted treatments has expanded, with newer agents under investigation including antibody-drug conjugates, bispecific antibodies, and tyrosine kinase inhibitors.

Advanced biologics such as trastuzumab deruxtecan are being tested in patients who are resistant to first-line therapies, showing promise in clinical trials for improved efficacy. Combination therapies that integrate immunotherapy with HER2-targeted drugs are also under evaluation. These innovations reflect a growing pipeline of personalized treatments tailored to HER2 expression profiles and tumor characteristics in gastric cancers.

Where Is Demand for Testing and Treatment Growing, and Who Are the Key Stakeholders?

Adoption of HER2 testing and targeted therapy is growing across oncology centers, academic hospitals, and diagnostic laboratories. Demand is strongest in regions with high gastric cancer incidence, such as East Asia, parts of Eastern Europe, and Latin America. Japan, South Korea, and China represent major diagnostic and therapeutic markets due to well-developed cancer care systems and high testing penetration.

Stakeholders include oncologists, pathology laboratories, pharmaceutical companies, and diagnostic assay developers. Collaborations between diagnostic firms and drug manufacturers are supporting the development of companion diagnostics and therapy-linked assays. National cancer control programs and public health initiatives are further encouraging HER2 screening as part of broader efforts to improve cancer survival rates through biomarker-driven treatment models.

What Is Driving Growth in the HER2-Positive Gastric Cancer Market?

Growth in the HER2-positive gastric cancer market is driven by several factors including rising incidence of gastric cancer, increasing use of biomarker-based treatment planning, and expanding access to HER2-targeted therapies. Advances in diagnostic precision, including improved antibody-based tests and automated pathology workflows, are supporting accurate HER2 identification.

End-use expansion in oncology treatment centers, diagnostic labs, and personalized drug development programs is strengthening market adoption. Pipeline growth of HER2-directed biologics, extended indications of existing drugs, and supportive clinical guidelines are reinforcing therapeutic relevance. As personalized oncology continues to evolve, HER2 testing and therapy are expected to play a central role in managing a biologically distinct segment of gastric cancer patients.

SCOPE OF STUDY:

The report analyzes the HER2-Positive Gastric Cancer market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Treatment Type (Chemotherapy, Targeted Therapy, Immunotherapy, Combination Therapies); End-User (Hospitals End-User, Specialty Cancer Centers End-User, Other End-Users)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 41 Featured) -

  • Acepodia Biotech Inc.
  • Astellas Pharma Inc.
  • AstraZeneca PLC
  • Bavarian Nordic A/S
  • Bellicum Pharmaceuticals
  • BioInvent International AB
  • Bristol-Myers Squibb
  • Carisma Therapeutics Inc.
  • Celularity Inc.
  • Daiichi Sankyo Co., Ltd.
  • Genentech (Roche Group)
  • GeneQuantum Healthcare
  • Hengrui (Jiangsu HengRui Medicine)
  • Imugene Limited
  • Klus Pharma Inc.
  • MacroGenics, Inc.
  • Merck & Co., Inc.
  • Mersana Therapeutics, Inc.
  • Novartis AG
  • Pfizer Inc.
  • Pieris Pharmaceuticals, Inc.
  • Shanghai Miracogen Inc.
  • Zymeworks Inc.

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • World Market Trajectories
    • Tariff Impact on Global Supply Chain Patterns
    • HER2-Positive Gastric Cancer - Global Key Competitors Percentage Market Share in 2025 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Rising Incidence of Gastric and Gastroesophageal Junction Cancers Globally Drives Demand for HER2 Biomarker Testing
    • Increased Use of Targeted Therapy in Oncology Strengthens Business Case for HER2-Directed Treatments in Gastric Cancer
    • Regulatory Approvals of HER2-Targeting Drugs Beyond Breast Cancer Propel Market Expansion in Gastric Oncology
    • Advancements in IHC and FISH-Based HER2 Diagnostics Support Early Detection and Personalized Treatment Pathways
    • Emerging Combination Therapies with HER2 Inhibitors and Immune Checkpoint Blockade Generate Innovation Momentum
    • Rising Awareness Among Oncologists About HER2-Positive Subtypes Spurs Broader Molecular Testing in GI Tumors
    • Growth in Clinical Trials Targeting HER2 Overexpression in Gastric Cancer Expands Pipeline and Treatment Options
    • Integration of HER2 Testing in Standard Diagnostic Protocols Enhances Timely Identification of Eligible Patients
    • Increasing Prevalence of HER2 Heterogeneity in Gastric Tumors Drives Research in Precision Therapy Optimization
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World HER2-Positive Gastric Cancer Market Analysis of Annual Sales in US$ Thousand for Years 2014 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for HER2-Positive Gastric Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 3: World Historic Review for HER2-Positive Gastric Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 4: World 16-Year Perspective for HER2-Positive Gastric Cancer by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2014, 2025 & 2030
    • TABLE 5: World Recent Past, Current & Future Analysis for Chemotherapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 6: World Historic Review for Chemotherapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 7: World 16-Year Perspective for Chemotherapy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for Targeted Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 9: World Historic Review for Targeted Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 10: World 16-Year Perspective for Targeted Therapy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 11: World Recent Past, Current & Future Analysis for Immunotherapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 12: World Historic Review for Immunotherapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 13: World 16-Year Perspective for Immunotherapy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 14: World Recent Past, Current & Future Analysis for Combination Therapies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 15: World Historic Review for Combination Therapies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 16: World 16-Year Perspective for Combination Therapies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 17: World Recent Past, Current & Future Analysis for Hospitals End-User by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 18: World Historic Review for Hospitals End-User by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 19: World 16-Year Perspective for Hospitals End-User by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 20: World Recent Past, Current & Future Analysis for Specialty Cancer Centers End-User by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 21: World Historic Review for Specialty Cancer Centers End-User by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 22: World 16-Year Perspective for Specialty Cancer Centers End-User by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 23: World Recent Past, Current & Future Analysis for Other End-Users by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 24: World Historic Review for Other End-Users by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 25: World 16-Year Perspective for Other End-Users by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • HER2-Positive Gastric Cancer Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
    • TABLE 26: USA Recent Past, Current & Future Analysis for HER2-Positive Gastric Cancer by Treatment Type - Chemotherapy, Targeted Therapy, Immunotherapy and Combination Therapies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 27: USA Historic Review for HER2-Positive Gastric Cancer by Treatment Type - Chemotherapy, Targeted Therapy, Immunotherapy and Combination Therapies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 28: USA 16-Year Perspective for HER2-Positive Gastric Cancer by Treatment Type - Percentage Breakdown of Value Sales for Chemotherapy, Targeted Therapy, Immunotherapy and Combination Therapies for the Years 2014, 2025 & 2030
    • TABLE 29: USA Recent Past, Current & Future Analysis for HER2-Positive Gastric Cancer by End-user - Hospitals End-User, Specialty Cancer Centers End-User and Other End-Users - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 30: USA Historic Review for HER2-Positive Gastric Cancer by End-user - Hospitals End-User, Specialty Cancer Centers End-User and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 31: USA 16-Year Perspective for HER2-Positive Gastric Cancer by End-user - Percentage Breakdown of Value Sales for Hospitals End-User, Specialty Cancer Centers End-User and Other End-Users for the Years 2014, 2025 & 2030
  • CANADA
    • TABLE 32: Canada Recent Past, Current & Future Analysis for HER2-Positive Gastric Cancer by Treatment Type - Chemotherapy, Targeted Therapy, Immunotherapy and Combination Therapies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 33: Canada Historic Review for HER2-Positive Gastric Cancer by Treatment Type - Chemotherapy, Targeted Therapy, Immunotherapy and Combination Therapies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 34: Canada 16-Year Perspective for HER2-Positive Gastric Cancer by Treatment Type - Percentage Breakdown of Value Sales for Chemotherapy, Targeted Therapy, Immunotherapy and Combination Therapies for the Years 2014, 2025 & 2030
    • TABLE 35: Canada Recent Past, Current & Future Analysis for HER2-Positive Gastric Cancer by End-user - Hospitals End-User, Specialty Cancer Centers End-User and Other End-Users - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 36: Canada Historic Review for HER2-Positive Gastric Cancer by End-user - Hospitals End-User, Specialty Cancer Centers End-User and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 37: Canada 16-Year Perspective for HER2-Positive Gastric Cancer by End-user - Percentage Breakdown of Value Sales for Hospitals End-User, Specialty Cancer Centers End-User and Other End-Users for the Years 2014, 2025 & 2030
  • JAPAN
    • HER2-Positive Gastric Cancer Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
    • TABLE 38: Japan Recent Past, Current & Future Analysis for HER2-Positive Gastric Cancer by Treatment Type - Chemotherapy, Targeted Therapy, Immunotherapy and Combination Therapies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 39: Japan Historic Review for HER2-Positive Gastric Cancer by Treatment Type - Chemotherapy, Targeted Therapy, Immunotherapy and Combination Therapies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 40: Japan 16-Year Perspective for HER2-Positive Gastric Cancer by Treatment Type - Percentage Breakdown of Value Sales for Chemotherapy, Targeted Therapy, Immunotherapy and Combination Therapies for the Years 2014, 2025 & 2030
    • TABLE 41: Japan Recent Past, Current & Future Analysis for HER2-Positive Gastric Cancer by End-user - Hospitals End-User, Specialty Cancer Centers End-User and Other End-Users - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 42: Japan Historic Review for HER2-Positive Gastric Cancer by End-user - Hospitals End-User, Specialty Cancer Centers End-User and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 43: Japan 16-Year Perspective for HER2-Positive Gastric Cancer by End-user - Percentage Breakdown of Value Sales for Hospitals End-User, Specialty Cancer Centers End-User and Other End-Users for the Years 2014, 2025 & 2030
  • CHINA
    • HER2-Positive Gastric Cancer Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
    • TABLE 44: China Recent Past, Current & Future Analysis for HER2-Positive Gastric Cancer by Treatment Type - Chemotherapy, Targeted Therapy, Immunotherapy and Combination Therapies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 45: China Historic Review for HER2-Positive Gastric Cancer by Treatment Type - Chemotherapy, Targeted Therapy, Immunotherapy and Combination Therapies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 46: China 16-Year Perspective for HER2-Positive Gastric Cancer by Treatment Type - Percentage Breakdown of Value Sales for Chemotherapy, Targeted Therapy, Immunotherapy and Combination Therapies for the Years 2014, 2025 & 2030
    • TABLE 47: China Recent Past, Current & Future Analysis for HER2-Positive Gastric Cancer by End-user - Hospitals End-User, Specialty Cancer Centers End-User and Other End-Users - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 48: China Historic Review for HER2-Positive Gastric Cancer by End-user - Hospitals End-User, Specialty Cancer Centers End-User and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 49: China 16-Year Perspective for HER2-Positive Gastric Cancer by End-user - Percentage Breakdown of Value Sales for Hospitals End-User, Specialty Cancer Centers End-User and Other End-Users for the Years 2014, 2025 & 2030
  • EUROPE
    • HER2-Positive Gastric Cancer Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
    • TABLE 50: Europe Recent Past, Current & Future Analysis for HER2-Positive Gastric Cancer by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 51: Europe Historic Review for HER2-Positive Gastric Cancer by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 52: Europe 16-Year Perspective for HER2-Positive Gastric Cancer by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2014, 2025 & 2030
    • TABLE 53: Europe Recent Past, Current & Future Analysis for HER2-Positive Gastric Cancer by Treatment Type - Chemotherapy, Targeted Therapy, Immunotherapy and Combination Therapies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 54: Europe Historic Review for HER2-Positive Gastric Cancer by Treatment Type - Chemotherapy, Targeted Therapy, Immunotherapy and Combination Therapies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 55: Europe 16-Year Perspective for HER2-Positive Gastric Cancer by Treatment Type - Percentage Breakdown of Value Sales for Chemotherapy, Targeted Therapy, Immunotherapy and Combination Therapies for the Years 2014, 2025 & 2030
    • TABLE 56: Europe Recent Past, Current & Future Analysis for HER2-Positive Gastric Cancer by End-user - Hospitals End-User, Specialty Cancer Centers End-User and Other End-Users - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 57: Europe Historic Review for HER2-Positive Gastric Cancer by End-user - Hospitals End-User, Specialty Cancer Centers End-User and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 58: Europe 16-Year Perspective for HER2-Positive Gastric Cancer by End-user - Percentage Breakdown of Value Sales for Hospitals End-User, Specialty Cancer Centers End-User and Other End-Users for the Years 2014, 2025 & 2030
  • FRANCE
    • HER2-Positive Gastric Cancer Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
    • TABLE 59: France Recent Past, Current & Future Analysis for HER2-Positive Gastric Cancer by Treatment Type - Chemotherapy, Targeted Therapy, Immunotherapy and Combination Therapies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 60: France Historic Review for HER2-Positive Gastric Cancer by Treatment Type - Chemotherapy, Targeted Therapy, Immunotherapy and Combination Therapies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 61: France 16-Year Perspective for HER2-Positive Gastric Cancer by Treatment Type - Percentage Breakdown of Value Sales for Chemotherapy, Targeted Therapy, Immunotherapy and Combination Therapies for the Years 2014, 2025 & 2030
    • TABLE 62: France Recent Past, Current & Future Analysis for HER2-Positive Gastric Cancer by End-user - Hospitals End-User, Specialty Cancer Centers End-User and Other End-Users - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 63: France Historic Review for HER2-Positive Gastric Cancer by End-user - Hospitals End-User, Specialty Cancer Centers End-User and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 64: France 16-Year Perspective for HER2-Positive Gastric Cancer by End-user - Percentage Breakdown of Value Sales for Hospitals End-User, Specialty Cancer Centers End-User and Other End-Users for the Years 2014, 2025 & 2030
  • GERMANY
    • HER2-Positive Gastric Cancer Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
    • TABLE 65: Germany Recent Past, Current & Future Analysis for HER2-Positive Gastric Cancer by Treatment Type - Chemotherapy, Targeted Therapy, Immunotherapy and Combination Therapies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 66: Germany Historic Review for HER2-Positive Gastric Cancer by Treatment Type - Chemotherapy, Targeted Therapy, Immunotherapy and Combination Therapies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 67: Germany 16-Year Perspective for HER2-Positive Gastric Cancer by Treatment Type - Percentage Breakdown of Value Sales for Chemotherapy, Targeted Therapy, Immunotherapy and Combination Therapies for the Years 2014, 2025 & 2030
    • TABLE 68: Germany Recent Past, Current & Future Analysis for HER2-Positive Gastric Cancer by End-user - Hospitals End-User, Specialty Cancer Centers End-User and Other End-Users - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 69: Germany Historic Review for HER2-Positive Gastric Cancer by End-user - Hospitals End-User, Specialty Cancer Centers End-User and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 70: Germany 16-Year Perspective for HER2-Positive Gastric Cancer by End-user - Percentage Breakdown of Value Sales for Hospitals End-User, Specialty Cancer Centers End-User and Other End-Users for the Years 2014, 2025 & 2030
  • ITALY
    • TABLE 71: Italy Recent Past, Current & Future Analysis for HER2-Positive Gastric Cancer by Treatment Type - Chemotherapy, Targeted Therapy, Immunotherapy and Combination Therapies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 72: Italy Historic Review for HER2-Positive Gastric Cancer by Treatment Type - Chemotherapy, Targeted Therapy, Immunotherapy and Combination Therapies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 73: Italy 16-Year Perspective for HER2-Positive Gastric Cancer by Treatment Type - Percentage Breakdown of Value Sales for Chemotherapy, Targeted Therapy, Immunotherapy and Combination Therapies for the Years 2014, 2025 & 2030
    • TABLE 74: Italy Recent Past, Current & Future Analysis for HER2-Positive Gastric Cancer by End-user - Hospitals End-User, Specialty Cancer Centers End-User and Other End-Users - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 75: Italy Historic Review for HER2-Positive Gastric Cancer by End-user - Hospitals End-User, Specialty Cancer Centers End-User and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 76: Italy 16-Year Perspective for HER2-Positive Gastric Cancer by End-user - Percentage Breakdown of Value Sales for Hospitals End-User, Specialty Cancer Centers End-User and Other End-Users for the Years 2014, 2025 & 2030
  • UNITED KINGDOM
    • HER2-Positive Gastric Cancer Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
    • TABLE 77: UK Recent Past, Current & Future Analysis for HER2-Positive Gastric Cancer by Treatment Type - Chemotherapy, Targeted Therapy, Immunotherapy and Combination Therapies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 78: UK Historic Review for HER2-Positive Gastric Cancer by Treatment Type - Chemotherapy, Targeted Therapy, Immunotherapy and Combination Therapies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 79: UK 16-Year Perspective for HER2-Positive Gastric Cancer by Treatment Type - Percentage Breakdown of Value Sales for Chemotherapy, Targeted Therapy, Immunotherapy and Combination Therapies for the Years 2014, 2025 & 2030
    • TABLE 80: UK Recent Past, Current & Future Analysis for HER2-Positive Gastric Cancer by End-user - Hospitals End-User, Specialty Cancer Centers End-User and Other End-Users - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 81: UK Historic Review for HER2-Positive Gastric Cancer by End-user - Hospitals End-User, Specialty Cancer Centers End-User and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 82: UK 16-Year Perspective for HER2-Positive Gastric Cancer by End-user - Percentage Breakdown of Value Sales for Hospitals End-User, Specialty Cancer Centers End-User and Other End-Users for the Years 2014, 2025 & 2030
  • SPAIN
    • TABLE 83: Spain Recent Past, Current & Future Analysis for HER2-Positive Gastric Cancer by Treatment Type - Chemotherapy, Targeted Therapy, Immunotherapy and Combination Therapies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 84: Spain Historic Review for HER2-Positive Gastric Cancer by Treatment Type - Chemotherapy, Targeted Therapy, Immunotherapy and Combination Therapies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 85: Spain 16-Year Perspective for HER2-Positive Gastric Cancer by Treatment Type - Percentage Breakdown of Value Sales for Chemotherapy, Targeted Therapy, Immunotherapy and Combination Therapies for the Years 2014, 2025 & 2030
    • TABLE 86: Spain Recent Past, Current & Future Analysis for HER2-Positive Gastric Cancer by End-user - Hospitals End-User, Specialty Cancer Centers End-User and Other End-Users - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 87: Spain Historic Review for HER2-Positive Gastric Cancer by End-user - Hospitals End-User, Specialty Cancer Centers End-User and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 88: Spain 16-Year Perspective for HER2-Positive Gastric Cancer by End-user - Percentage Breakdown of Value Sales for Hospitals End-User, Specialty Cancer Centers End-User and Other End-Users for the Years 2014, 2025 & 2030
  • RUSSIA
    • TABLE 89: Russia Recent Past, Current & Future Analysis for HER2-Positive Gastric Cancer by Treatment Type - Chemotherapy, Targeted Therapy, Immunotherapy and Combination Therapies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 90: Russia Historic Review for HER2-Positive Gastric Cancer by Treatment Type - Chemotherapy, Targeted Therapy, Immunotherapy and Combination Therapies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 91: Russia 16-Year Perspective for HER2-Positive Gastric Cancer by Treatment Type - Percentage Breakdown of Value Sales for Chemotherapy, Targeted Therapy, Immunotherapy and Combination Therapies for the Years 2014, 2025 & 2030
    • TABLE 92: Russia Recent Past, Current & Future Analysis for HER2-Positive Gastric Cancer by End-user - Hospitals End-User, Specialty Cancer Centers End-User and Other End-Users - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 93: Russia Historic Review for HER2-Positive Gastric Cancer by End-user - Hospitals End-User, Specialty Cancer Centers End-User and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 94: Russia 16-Year Perspective for HER2-Positive Gastric Cancer by End-user - Percentage Breakdown of Value Sales for Hospitals End-User, Specialty Cancer Centers End-User and Other End-Users for the Years 2014, 2025 & 2030
  • REST OF EUROPE
    • TABLE 95: Rest of Europe Recent Past, Current & Future Analysis for HER2-Positive Gastric Cancer by Treatment Type - Chemotherapy, Targeted Therapy, Immunotherapy and Combination Therapies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 96: Rest of Europe Historic Review for HER2-Positive Gastric Cancer by Treatment Type - Chemotherapy, Targeted Therapy, Immunotherapy and Combination Therapies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 97: Rest of Europe 16-Year Perspective for HER2-Positive Gastric Cancer by Treatment Type - Percentage Breakdown of Value Sales for Chemotherapy, Targeted Therapy, Immunotherapy and Combination Therapies for the Years 2014, 2025 & 2030
    • TABLE 98: Rest of Europe Recent Past, Current & Future Analysis for HER2-Positive Gastric Cancer by End-user - Hospitals End-User, Specialty Cancer Centers End-User and Other End-Users - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 99: Rest of Europe Historic Review for HER2-Positive Gastric Cancer by End-user - Hospitals End-User, Specialty Cancer Centers End-User and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 100: Rest of Europe 16-Year Perspective for HER2-Positive Gastric Cancer by End-user - Percentage Breakdown of Value Sales for Hospitals End-User, Specialty Cancer Centers End-User and Other End-Users for the Years 2014, 2025 & 2030
  • ASIA-PACIFIC
    • HER2-Positive Gastric Cancer Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
    • TABLE 101: Asia-Pacific Recent Past, Current & Future Analysis for HER2-Positive Gastric Cancer by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 102: Asia-Pacific Historic Review for HER2-Positive Gastric Cancer by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 103: Asia-Pacific 16-Year Perspective for HER2-Positive Gastric Cancer by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2014, 2025 & 2030
    • TABLE 104: Asia-Pacific Recent Past, Current & Future Analysis for HER2-Positive Gastric Cancer by Treatment Type - Chemotherapy, Targeted Therapy, Immunotherapy and Combination Therapies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 105: Asia-Pacific Historic Review for HER2-Positive Gastric Cancer by Treatment Type - Chemotherapy, Targeted Therapy, Immunotherapy and Combination Therapies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 106: Asia-Pacific 16-Year Perspective for HER2-Positive Gastric Cancer by Treatment Type - Percentage Breakdown of Value Sales for Chemotherapy, Targeted Therapy, Immunotherapy and Combination Therapies for the Years 2014, 2025 & 2030
    • TABLE 107: Asia-Pacific Recent Past, Current & Future Analysis for HER2-Positive Gastric Cancer by End-user - Hospitals End-User, Specialty Cancer Centers End-User and Other End-Users - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 108: Asia-Pacific Historic Review for HER2-Positive Gastric Cancer by End-user - Hospitals End-User, Specialty Cancer Centers End-User and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 109: Asia-Pacific 16-Year Perspective for HER2-Positive Gastric Cancer by End-user - Percentage Breakdown of Value Sales for Hospitals End-User, Specialty Cancer Centers End-User and Other End-Users for the Years 2014, 2025 & 2030
  • AUSTRALIA
    • HER2-Positive Gastric Cancer Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)
    • TABLE 110: Australia Recent Past, Current & Future Analysis for HER2-Positive Gastric Cancer by Treatment Type - Chemotherapy, Targeted Therapy, Immunotherapy and Combination Therapies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 111: Australia Historic Review for HER2-Positive Gastric Cancer by Treatment Type - Chemotherapy, Targeted Therapy, Immunotherapy and Combination Therapies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 112: Australia 16-Year Perspective for HER2-Positive Gastric Cancer by Treatment Type - Percentage Breakdown of Value Sales for Chemotherapy, Targeted Therapy, Immunotherapy and Combination Therapies for the Years 2014, 2025 & 2030
    • TABLE 113: Australia Recent Past, Current & Future Analysis for HER2-Positive Gastric Cancer by End-user - Hospitals End-User, Specialty Cancer Centers End-User and Other End-Users - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 114: Australia Historic Review for HER2-Positive Gastric Cancer by End-user - Hospitals End-User, Specialty Cancer Centers End-User and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 115: Australia 16-Year Perspective for HER2-Positive Gastric Cancer by End-user - Percentage Breakdown of Value Sales for Hospitals End-User, Specialty Cancer Centers End-User and Other End-Users for the Years 2014, 2025 & 2030
  • INDIA
    • HER2-Positive Gastric Cancer Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)
    • TABLE 116: India Recent Past, Current & Future Analysis for HER2-Positive Gastric Cancer by Treatment Type - Chemotherapy, Targeted Therapy, Immunotherapy and Combination Therapies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 117: India Historic Review for HER2-Positive Gastric Cancer by Treatment Type - Chemotherapy, Targeted Therapy, Immunotherapy and Combination Therapies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 118: India 16-Year Perspective for HER2-Positive Gastric Cancer by Treatment Type - Percentage Breakdown of Value Sales for Chemotherapy, Targeted Therapy, Immunotherapy and Combination Therapies for the Years 2014, 2025 & 2030
    • TABLE 119: India Recent Past, Current & Future Analysis for HER2-Positive Gastric Cancer by End-user - Hospitals End-User, Specialty Cancer Centers End-User and Other End-Users - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 120: India Historic Review for HER2-Positive Gastric Cancer by End-user - Hospitals End-User, Specialty Cancer Centers End-User and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 121: India 16-Year Perspective for HER2-Positive Gastric Cancer by End-user - Percentage Breakdown of Value Sales for Hospitals End-User, Specialty Cancer Centers End-User and Other End-Users for the Years 2014, 2025 & 2030
  • SOUTH KOREA
    • TABLE 122: South Korea Recent Past, Current & Future Analysis for HER2-Positive Gastric Cancer by Treatment Type - Chemotherapy, Targeted Therapy, Immunotherapy and Combination Therapies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 123: South Korea Historic Review for HER2-Positive Gastric Cancer by Treatment Type - Chemotherapy, Targeted Therapy, Immunotherapy and Combination Therapies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 124: South Korea 16-Year Perspective for HER2-Positive Gastric Cancer by Treatment Type - Percentage Breakdown of Value Sales for Chemotherapy, Targeted Therapy, Immunotherapy and Combination Therapies for the Years 2014, 2025 & 2030
    • TABLE 125: South Korea Recent Past, Current & Future Analysis for HER2-Positive Gastric Cancer by End-user - Hospitals End-User, Specialty Cancer Centers End-User and Other End-Users - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 126: South Korea Historic Review for HER2-Positive Gastric Cancer by End-user - Hospitals End-User, Specialty Cancer Centers End-User and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 127: South Korea 16-Year Perspective for HER2-Positive Gastric Cancer by End-user - Percentage Breakdown of Value Sales for Hospitals End-User, Specialty Cancer Centers End-User and Other End-Users for the Years 2014, 2025 & 2030
  • REST OF ASIA-PACIFIC
    • TABLE 128: Rest of Asia-Pacific Recent Past, Current & Future Analysis for HER2-Positive Gastric Cancer by Treatment Type - Chemotherapy, Targeted Therapy, Immunotherapy and Combination Therapies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 129: Rest of Asia-Pacific Historic Review for HER2-Positive Gastric Cancer by Treatment Type - Chemotherapy, Targeted Therapy, Immunotherapy and Combination Therapies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 130: Rest of Asia-Pacific 16-Year Perspective for HER2-Positive Gastric Cancer by Treatment Type - Percentage Breakdown of Value Sales for Chemotherapy, Targeted Therapy, Immunotherapy and Combination Therapies for the Years 2014, 2025 & 2030
    • TABLE 131: Rest of Asia-Pacific Recent Past, Current & Future Analysis for HER2-Positive Gastric Cancer by End-user - Hospitals End-User, Specialty Cancer Centers End-User and Other End-Users - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 132: Rest of Asia-Pacific Historic Review for HER2-Positive Gastric Cancer by End-user - Hospitals End-User, Specialty Cancer Centers End-User and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 133: Rest of Asia-Pacific 16-Year Perspective for HER2-Positive Gastric Cancer by End-user - Percentage Breakdown of Value Sales for Hospitals End-User, Specialty Cancer Centers End-User and Other End-Users for the Years 2014, 2025 & 2030
  • LATIN AMERICA
    • HER2-Positive Gastric Cancer Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
    • TABLE 134: Latin America Recent Past, Current & Future Analysis for HER2-Positive Gastric Cancer by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 135: Latin America Historic Review for HER2-Positive Gastric Cancer by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 136: Latin America 16-Year Perspective for HER2-Positive Gastric Cancer by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2014, 2025 & 2030
    • TABLE 137: Latin America Recent Past, Current & Future Analysis for HER2-Positive Gastric Cancer by Treatment Type - Chemotherapy, Targeted Therapy, Immunotherapy and Combination Therapies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 138: Latin America Historic Review for HER2-Positive Gastric Cancer by Treatment Type - Chemotherapy, Targeted Therapy, Immunotherapy and Combination Therapies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 139: Latin America 16-Year Perspective for HER2-Positive Gastric Cancer by Treatment Type - Percentage Breakdown of Value Sales for Chemotherapy, Targeted Therapy, Immunotherapy and Combination Therapies for the Years 2014, 2025 & 2030
    • TABLE 140: Latin America Recent Past, Current & Future Analysis for HER2-Positive Gastric Cancer by End-user - Hospitals End-User, Specialty Cancer Centers End-User and Other End-Users - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 141: Latin America Historic Review for HER2-Positive Gastric Cancer by End-user - Hospitals End-User, Specialty Cancer Centers End-User and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 142: Latin America 16-Year Perspective for HER2-Positive Gastric Cancer by End-user - Percentage Breakdown of Value Sales for Hospitals End-User, Specialty Cancer Centers End-User and Other End-Users for the Years 2014, 2025 & 2030
  • ARGENTINA
    • TABLE 143: Argentina Recent Past, Current & Future Analysis for HER2-Positive Gastric Cancer by Treatment Type - Chemotherapy, Targeted Therapy, Immunotherapy and Combination Therapies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 144: Argentina Historic Review for HER2-Positive Gastric Cancer by Treatment Type - Chemotherapy, Targeted Therapy, Immunotherapy and Combination Therapies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 145: Argentina 16-Year Perspective for HER2-Positive Gastric Cancer by Treatment Type - Percentage Breakdown of Value Sales for Chemotherapy, Targeted Therapy, Immunotherapy and Combination Therapies for the Years 2014, 2025 & 2030
    • TABLE 146: Argentina Recent Past, Current & Future Analysis for HER2-Positive Gastric Cancer by End-user - Hospitals End-User, Specialty Cancer Centers End-User and Other End-Users - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 147: Argentina Historic Review for HER2-Positive Gastric Cancer by End-user - Hospitals End-User, Specialty Cancer Centers End-User and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 148: Argentina 16-Year Perspective for HER2-Positive Gastric Cancer by End-user - Percentage Breakdown of Value Sales for Hospitals End-User, Specialty Cancer Centers End-User and Other End-Users for the Years 2014, 2025 & 2030
  • BRAZIL
    • TABLE 149: Brazil Recent Past, Current & Future Analysis for HER2-Positive Gastric Cancer by Treatment Type - Chemotherapy, Targeted Therapy, Immunotherapy and Combination Therapies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 150: Brazil Historic Review for HER2-Positive Gastric Cancer by Treatment Type - Chemotherapy, Targeted Therapy, Immunotherapy and Combination Therapies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 151: Brazil 16-Year Perspective for HER2-Positive Gastric Cancer by Treatment Type - Percentage Breakdown of Value Sales for Chemotherapy, Targeted Therapy, Immunotherapy and Combination Therapies for the Years 2014, 2025 & 2030
    • TABLE 152: Brazil Recent Past, Current & Future Analysis for HER2-Positive Gastric Cancer by End-user - Hospitals End-User, Specialty Cancer Centers End-User and Other End-Users - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 153: Brazil Historic Review for HER2-Positive Gastric Cancer by End-user - Hospitals End-User, Specialty Cancer Centers End-User and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 154: Brazil 16-Year Perspective for HER2-Positive Gastric Cancer by End-user - Percentage Breakdown of Value Sales for Hospitals End-User, Specialty Cancer Centers End-User and Other End-Users for the Years 2014, 2025 & 2030
  • MEXICO
    • TABLE 155: Mexico Recent Past, Current & Future Analysis for HER2-Positive Gastric Cancer by Treatment Type - Chemotherapy, Targeted Therapy, Immunotherapy and Combination Therapies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 156: Mexico Historic Review for HER2-Positive Gastric Cancer by Treatment Type - Chemotherapy, Targeted Therapy, Immunotherapy and Combination Therapies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 157: Mexico 16-Year Perspective for HER2-Positive Gastric Cancer by Treatment Type - Percentage Breakdown of Value Sales for Chemotherapy, Targeted Therapy, Immunotherapy and Combination Therapies for the Years 2014, 2025 & 2030
    • TABLE 158: Mexico Recent Past, Current & Future Analysis for HER2-Positive Gastric Cancer by End-user - Hospitals End-User, Specialty Cancer Centers End-User and Other End-Users - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 159: Mexico Historic Review for HER2-Positive Gastric Cancer by End-user - Hospitals End-User, Specialty Cancer Centers End-User and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 160: Mexico 16-Year Perspective for HER2-Positive Gastric Cancer by End-user - Percentage Breakdown of Value Sales for Hospitals End-User, Specialty Cancer Centers End-User and Other End-Users for the Years 2014, 2025 & 2030
  • REST OF LATIN AMERICA
    • TABLE 161: Rest of Latin America Recent Past, Current & Future Analysis for HER2-Positive Gastric Cancer by Treatment Type - Chemotherapy, Targeted Therapy, Immunotherapy and Combination Therapies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 162: Rest of Latin America Historic Review for HER2-Positive Gastric Cancer by Treatment Type - Chemotherapy, Targeted Therapy, Immunotherapy and Combination Therapies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 163: Rest of Latin America 16-Year Perspective for HER2-Positive Gastric Cancer by Treatment Type - Percentage Breakdown of Value Sales for Chemotherapy, Targeted Therapy, Immunotherapy and Combination Therapies for the Years 2014, 2025 & 2030
    • TABLE 164: Rest of Latin America Recent Past, Current & Future Analysis for HER2-Positive Gastric Cancer by End-user - Hospitals End-User, Specialty Cancer Centers End-User and Other End-Users - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 165: Rest of Latin America Historic Review for HER2-Positive Gastric Cancer by End-user - Hospitals End-User, Specialty Cancer Centers End-User and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 166: Rest of Latin America 16-Year Perspective for HER2-Positive Gastric Cancer by End-user - Percentage Breakdown of Value Sales for Hospitals End-User, Specialty Cancer Centers End-User and Other End-Users for the Years 2014, 2025 & 2030
  • MIDDLE EAST
    • HER2-Positive Gastric Cancer Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
    • TABLE 167: Middle East Recent Past, Current & Future Analysis for HER2-Positive Gastric Cancer by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 168: Middle East Historic Review for HER2-Positive Gastric Cancer by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 169: Middle East 16-Year Perspective for HER2-Positive Gastric Cancer by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2014, 2025 & 2030
    • TABLE 170: Middle East Recent Past, Current & Future Analysis for HER2-Positive Gastric Cancer by Treatment Type - Chemotherapy, Targeted Therapy, Immunotherapy and Combination Therapies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 171: Middle East Historic Review for HER2-Positive Gastric Cancer by Treatment Type - Chemotherapy, Targeted Therapy, Immunotherapy and Combination Therapies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 172: Middle East 16-Year Perspective for HER2-Positive Gastric Cancer by Treatment Type - Percentage Breakdown of Value Sales for Chemotherapy, Targeted Therapy, Immunotherapy and Combination Therapies for the Years 2014, 2025 & 2030
    • TABLE 173: Middle East Recent Past, Current & Future Analysis for HER2-Positive Gastric Cancer by End-user - Hospitals End-User, Specialty Cancer Centers End-User and Other End-Users - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 174: Middle East Historic Review for HER2-Positive Gastric Cancer by End-user - Hospitals End-User, Specialty Cancer Centers End-User and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 175: Middle East 16-Year Perspective for HER2-Positive Gastric Cancer by End-user - Percentage Breakdown of Value Sales for Hospitals End-User, Specialty Cancer Centers End-User and Other End-Users for the Years 2014, 2025 & 2030
  • IRAN
    • TABLE 176: Iran Recent Past, Current & Future Analysis for HER2-Positive Gastric Cancer by Treatment Type - Chemotherapy, Targeted Therapy, Immunotherapy and Combination Therapies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 177: Iran Historic Review for HER2-Positive Gastric Cancer by Treatment Type - Chemotherapy, Targeted Therapy, Immunotherapy and Combination Therapies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 178: Iran 16-Year Perspective for HER2-Positive Gastric Cancer by Treatment Type - Percentage Breakdown of Value Sales for Chemotherapy, Targeted Therapy, Immunotherapy and Combination Therapies for the Years 2014, 2025 & 2030
    • TABLE 179: Iran Recent Past, Current & Future Analysis for HER2-Positive Gastric Cancer by End-user - Hospitals End-User, Specialty Cancer Centers End-User and Other End-Users - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 180: Iran Historic Review for HER2-Positive Gastric Cancer by End-user - Hospitals End-User, Specialty Cancer Centers End-User and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 181: Iran 16-Year Perspective for HER2-Positive Gastric Cancer by End-user - Percentage Breakdown of Value Sales for Hospitals End-User, Specialty Cancer Centers End-User and Other End-Users for the Years 2014, 2025 & 2030
  • ISRAEL
    • TABLE 182: Israel Recent Past, Current & Future Analysis for HER2-Positive Gastric Cancer by Treatment Type - Chemotherapy, Targeted Therapy, Immunotherapy and Combination Therapies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 183: Israel Historic Review for HER2-Positive Gastric Cancer by Treatment Type - Chemotherapy, Targeted Therapy, Immunotherapy and Combination Therapies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 184: Israel 16-Year Perspective for HER2-Positive Gastric Cancer by Treatment Type - Percentage Breakdown of Value Sales for Chemotherapy, Targeted Therapy, Immunotherapy and Combination Therapies for the Years 2014, 2025 & 2030
    • TABLE 185: Israel Recent Past, Current & Future Analysis for HER2-Positive Gastric Cancer by End-user - Hospitals End-User, Specialty Cancer Centers End-User and Other End-Users - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 186: Israel Historic Review for HER2-Positive Gastric Cancer by End-user - Hospitals End-User, Specialty Cancer Centers End-User and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 187: Israel 16-Year Perspective for HER2-Positive Gastric Cancer by End-user - Percentage Breakdown of Value Sales for Hospitals End-User, Specialty Cancer Centers End-User and Other End-Users for the Years 2014, 2025 & 2030
  • SAUDI ARABIA
    • TABLE 188: Saudi Arabia Recent Past, Current & Future Analysis for HER2-Positive Gastric Cancer by Treatment Type - Chemotherapy, Targeted Therapy, Immunotherapy and Combination Therapies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 189: Saudi Arabia Historic Review for HER2-Positive Gastric Cancer by Treatment Type - Chemotherapy, Targeted Therapy, Immunotherapy and Combination Therapies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 190: Saudi Arabia 16-Year Perspective for HER2-Positive Gastric Cancer by Treatment Type - Percentage Breakdown of Value Sales for Chemotherapy, Targeted Therapy, Immunotherapy and Combination Therapies for the Years 2014, 2025 & 2030
    • TABLE 191: Saudi Arabia Recent Past, Current & Future Analysis for HER2-Positive Gastric Cancer by End-user - Hospitals End-User, Specialty Cancer Centers End-User and Other End-Users - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 192: Saudi Arabia Historic Review for HER2-Positive Gastric Cancer by End-user - Hospitals End-User, Specialty Cancer Centers End-User and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 193: Saudi Arabia 16-Year Perspective for HER2-Positive Gastric Cancer by End-user - Percentage Breakdown of Value Sales for Hospitals End-User, Specialty Cancer Centers End-User and Other End-Users for the Years 2014, 2025 & 2030
  • UNITED ARAB EMIRATES
    • TABLE 194: UAE Recent Past, Current & Future Analysis for HER2-Positive Gastric Cancer by Treatment Type - Chemotherapy, Targeted Therapy, Immunotherapy and Combination Therapies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 195: UAE Historic Review for HER2-Positive Gastric Cancer by Treatment Type - Chemotherapy, Targeted Therapy, Immunotherapy and Combination Therapies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 196: UAE 16-Year Perspective for HER2-Positive Gastric Cancer by Treatment Type - Percentage Breakdown of Value Sales for Chemotherapy, Targeted Therapy, Immunotherapy and Combination Therapies for the Years 2014, 2025 & 2030
    • TABLE 197: UAE Recent Past, Current & Future Analysis for HER2-Positive Gastric Cancer by End-user - Hospitals End-User, Specialty Cancer Centers End-User and Other End-Users - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 198: UAE Historic Review for HER2-Positive Gastric Cancer by End-user - Hospitals End-User, Specialty Cancer Centers End-User and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 199: UAE 16-Year Perspective for HER2-Positive Gastric Cancer by End-user - Percentage Breakdown of Value Sales for Hospitals End-User, Specialty Cancer Centers End-User and Other End-Users for the Years 2014, 2025 & 2030
  • REST OF MIDDLE EAST
    • TABLE 200: Rest of Middle East Recent Past, Current & Future Analysis for HER2-Positive Gastric Cancer by Treatment Type - Chemotherapy, Targeted Therapy, Immunotherapy and Combination Therapies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 201: Rest of Middle East Historic Review for HER2-Positive Gastric Cancer by Treatment Type - Chemotherapy, Targeted Therapy, Immunotherapy and Combination Therapies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 202: Rest of Middle East 16-Year Perspective for HER2-Positive Gastric Cancer by Treatment Type - Percentage Breakdown of Value Sales for Chemotherapy, Targeted Therapy, Immunotherapy and Combination Therapies for the Years 2014, 2025 & 2030
    • TABLE 203: Rest of Middle East Recent Past, Current & Future Analysis for HER2-Positive Gastric Cancer by End-user - Hospitals End-User, Specialty Cancer Centers End-User and Other End-Users - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 204: Rest of Middle East Historic Review for HER2-Positive Gastric Cancer by End-user - Hospitals End-User, Specialty Cancer Centers End-User and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 205: Rest of Middle East 16-Year Perspective for HER2-Positive Gastric Cancer by End-user - Percentage Breakdown of Value Sales for Hospitals End-User, Specialty Cancer Centers End-User and Other End-Users for the Years 2014, 2025 & 2030
  • AFRICA
    • HER2-Positive Gastric Cancer Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)
    • TABLE 206: Africa Recent Past, Current & Future Analysis for HER2-Positive Gastric Cancer by Treatment Type - Chemotherapy, Targeted Therapy, Immunotherapy and Combination Therapies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 207: Africa Historic Review for HER2-Positive Gastric Cancer by Treatment Type - Chemotherapy, Targeted Therapy, Immunotherapy and Combination Therapies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 208: Africa 16-Year Perspective for HER2-Positive Gastric Cancer by Treatment Type - Percentage Breakdown of Value Sales for Chemotherapy, Targeted Therapy, Immunotherapy and Combination Therapies for the Years 2014, 2025 & 2030
    • TABLE 209: Africa Recent Past, Current & Future Analysis for HER2-Positive Gastric Cancer by End-user - Hospitals End-User, Specialty Cancer Centers End-User and Other End-Users - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 210: Africa Historic Review for HER2-Positive Gastric Cancer by End-user - Hospitals End-User, Specialty Cancer Centers End-User and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 211: Africa 16-Year Perspective for HER2-Positive Gastric Cancer by End-user - Percentage Breakdown of Value Sales for Hospitals End-User, Specialty Cancer Centers End-User and Other End-Users for the Years 2014, 2025 & 2030

IV. COMPETITION